The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Is sorafenib effective in colorectal cancer? Definition of resistance indicators and impact of potential comedications.
C. C. Schimanski
Research Funding - colorectal cancer
P. R. Galle
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Pfizer; Roche
Honoraria - Bayer; Bristol-Myers Squibb; Pfizer; Roche
M. H. Moehler
Honoraria - Bayer; Bristol-Myers Squibb; Pfizer; Roche